Like
Like {likecount}
({likecount})
Regulatory T cells could lead to new immunotherapies aimed at treating multiple sclerosis
Regulatory T cells (green) shown interacting with pathogenic Th17 cells (red) near collagen fibers (blue) in the spinal cord in a model of multiple sclerosis.


In a new University of California, Irvine-led study, researchers have discovered how regulatory T cells (Treg) are instrumental in limiting the damage caused to the spinal cord in diseases like multiple sclerosis (MS).

Published in the Proceedings of the National Academy of Sciences, the results of the study help explain how Treg cells prevent autoimmunity and dampen immune responses, specifically the negative effects of type 17 helper T cells (Th17) which are known to drive the progression of several autoimmune diseases.

This new study, which builds on recent research that identified pathogenic Th17 cells and their role in the progression of several autoimmune diseases, showed how the inhibition of Th17 cells by Treg cells enabled partial recovery from paralysis.  This finding demonstrates how autoimmune diseases may be effectively targeted using Treg-based cellular therapies.

“We discovered a unique ‘repetitive scanning motility’ by which Treg cells (the good guys) dampen calcium signaling in pathogenic Th17 cells (the bad guys), and help to resolve neuroinflammation and limit reactivation of Th17 cells in the spinal cord,” explained Shivashankar Othy, PhD, lead author of the study with Amit Jairaman, PhD, both project scientists in the Cahalan Lab at UCI.

Senior author, Michael D. Cahalan, PhD, distinguished professor and chair of the Department of Physiology & Biophysics at the UCI School of Medicine, added, “Building on our years of expertise in immunoimaging and calcium signaling, this study highlights Th17 and Treg cell interactions, their motility characteristics, and intracellular signaling, thus providing new insights into the pathophysiology of MS. Our results illustrate how a regulatory T cell-based immunotherapy may be instrumental in limiting demyelination in MS.”

This research was supported in part by the National Institutes of Health.

 Back to Top

COMMENTS (0)

POST A COMMENT

Your Name *

jparpana@uci.edu

Your Comment *

 Send me an email when a new comment is posted.
Please type the code from the image above.

In This Issue
Home
Cancer treatment without side effects?
Cognitive decline distorts political choices
Regulatory T cells could lead to new immunotherapies aimed at treating multiple sclerosis
Simple sugar found in human breast milk possible therapy for repairing myelin in multiple sclerosis
UCI-led study reveals significant restoration of retinal and visual function following gene therapy
Women with diabetes and high levels of coronary artery calcium at greater risk of death than men
Cartographers of the brain
New prediction algorithm identifies previously undetected cancer driver genes
Johanna Shapiro, PhD, receives Humanism Award from Society of Teachers of Family Medicine
Study finds new #MDsToo curriculum sensitizes faculty members and residents to mistreatment
The Bera Family Legacy: Education is a gift of a lifetime
Medical Students write book: Diary of a Med Student
Dr. Susan M. O'Brien named ‘Giant of Cancer Care’
Family medicine resident reflects on Covid-19
UCI Health recognized for surgical excellence by the American College of Surgeons
UCI Health honored as Healthcare Hero Honoree of the year by CHIOC
New chairs appointed for the Departments of Neurology, Pediatrics and Dermatology
Uzoma Mmeje joins Department of Orthopaedic Surgery as CAO
© 2025 The Regents of the University of California. All rights reserved.